

DAFTAR PUSTAKA

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021;71(3):209–49.
2. Pandey. American Cancer Society. About Cervical Cancer. [cancer.org/18002272345](https://www.cancer.org/18002272345). :1–9
W Am cancer Soc. :1–9.
3. Hoang Dang Phan N, Thanh Nguyen T, Thanh Vo N, Tuyet Thi Le T, Bao Hoang Tran T, Kim Truong P, et al. Epidemiology, Incidence, Mortality of Cervical Cancer in Southeast Asia and their Relationship: An Update Report. *Asian J Pharm Res Heal Care.* 2020;12(3):97–101.
4. The Global Cancer Observatory. Cancer Incident in Indonesia. *Int Agency Res Cancer.* 2020;858:1–2.
5. Indonesia BRKPDSP. Kanker di Indonesia tahun 2014. Data Histopatologik. Yayasan Kanker Indonesia. Jakarta .2018.
6. Nuranna L, Fahrudin A. Survival Rate of Cervical Cancer in National Referral Hospital in 2012 - 2014. 2014;51(2):145–50.
7. Matsuo K, Mandelbaum RS, Machida H, Purushotham S, Grubbs BH, Roman LD, et al. Association of tumor differentiation grade and survival of women with squamous cell carcinoma of the uterine cervix. *J Gynecol Oncol.* 2018;29(6):1–12.
8. Mendaza S, Fernández-Irigoyen J, Santamaría E, Zudaire T, Guarch R, Guerrero-Setas D, et al. Absence of nuclear p16 is a diagnostic and independent prognostic biomarker in squamous cell carcinoma of the cervix. *Int J Mol Sci.* 2020;21(6):1–16.
9. Áyen Á, Martínez YJ, Boulaiz H. Targeted gene delivery therapies for cervical cancer. *Cancers (Basel).* 2020;12(5).
10. Hu K, Wang W, Liu X, Meng Q, Zhang F. Comparison of treatment outcomes between squamous cell carcinoma and adenocarcinoma of cervix after definitive radiotherapy or concurrent chemoradiotherapy. 2018;(1):1–7.
11. Shimada M, Nishimura R, Nogawa TM, Hatae M. Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG / TGPU Intergroup Surveillance. 2013;(3):780–4.
12. Cree IA. (IARC WHO Classification of Tumours) coll. - WHO Classification of Female Genital Tumours-International Agency for Research on Cancer (IARC) (2020);342-51.

13. Fernandes A, Viveros- D. Human papillomavirus- - independent cervical cancer. 2022;(4):1–7.
14. R. K, C.V. R, S.R. S. Expression of P16 biomarker in squamous cell carcinoma of uterine cervix and its association with clinico-pathological parameters: A cross-sectional study. *Biomed Res Ther.* 2020;7(9):3954–61.
15. Rokutan-Kurata M, Minamiguchi S, Kataoka TR, Abiko K, Mandai M, Haga H. Uterine cervical squamous cell carcinoma without p16 (CDKN2A) expression: Heterogeneous causes of an unusual immunophenotype. *Pathol Int* [Internet].2020;70(7):413–21. Available from: <http://dx.doi.org/10.1111/pin.12930>
16. Da Mata S, Ferreira J, Nicolás I, Esteves S, Esteves G, Lérias S, et al. P16 and hvp genotype significance in hpv-associated cervical cancer-a large cohort of two tertiary referral centers. *Int J Mol Sci.* 2021;22(5):1–13.
17. Nicolás I, Saco A, Barnadas E, Marimon L, Rakislova N, Fusté P, et al. Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. *Mod Pathol* [Internet]. Available from: <http://dx.doi.org/10.1038/s41379-019-0360-3>
18. Hota S, Das TK. Expression of p16 and Galectin3 in Squamous Cell Carcinoma of Uterine Cervix, in Relation to the Histomorphological Variants: A Cross-sectional Analysis. *J Clin DIAGNOSTIC Res.* 2021;10–5.
19. Lin J, Albers AE, Qin J, Kaufmann AM. Prognostic Significance of Overexpressed p16 INK4a in Patients with Cervical Cancer : A Meta-Analysis. 2014;9(9).
20. Press A, Wc L, Radarweg UK, Box PO, Amsterdam AE, House L, et al. Working together to grow libraries in developing countries. 2016. 10–12 p.
21. Kurman RJ, Carcangiu ML, Herrington CS, Young RH. WHO Classification of Tumours of Female Reproductive Organs. *World Heal Organ Classif Tumours.* 2014;11–86.
22. Chan CK, Aimagambetova G, Ukybassova T, Kongrtay K, Azizan A. Human Papillomavirus Infection and Cervical Cancer: Epidemiology, Screening, and Vaccination - Review of Current Perspectives. Vol. 2019, *Journal of Oncology.* 2019.
23. Wahidin M, Febrianti R, Susanty F. Burden of Cervical Cancer in Indonesia: Findings From the Global Burden of Disease Study 1990–2017. In 2020. p. 213–7.
24. Xing B, Guo J, Sheng Y, Wu G, Zhao Y. Human Papillomavirus-Negative Cervical Cancer: A Comprehensive Review. *Front Oncol.* 2021;10(February):1–8.
25. Nucci MR, Oliva E. *Gynecologic Pathology.* Elsevier.2009;156-65.

26. Kurman RJ, Elleson LH, Ronnett BM. Blaustein's Pathology of the Female Genital Tract. 6th Ed. Springer.2011:265-70p
27. Crum CP, Nucci MR, Howitt BE, Granter SR, Parast MM, Boyd TK. Diagnostic gynecologic and obstetric pathology. Diagnostic Gynecologic and Obstetric Pathology. 2017. 1–1282 p.
28. Zhang S, Xu H, Zhang L, Qiao Y. Cervical cancer: Epidemiology, risk factors and screening. Chinese J Cancer Res. 2020;32(6):720–8.
29. Borcoman E, Le Tourneau C. Pembrolizumab in cervical cancer: Latest evidence and clinical usefulness. Vol. 9, Therapeutic Advances in Medical Oncology. 2017. p. 431–9.
30. Tang Y, Zhang AXJ, Chen G, Wu Y, Gu W. Prognostic and therapeutic TILs of cervical cancer—Current advances and future perspectives. Mol Ther - Oncolytics [Internet]. 2021;22:410–30. Available from: <https://doi.org/10.1016/j.omto.2021.07.006>
31. Jazaeri A. Safety and efficacy of adoptive cell transfer using autologous tumor infiltrating lymphocytes (LN-145) for treatment of recurrent, metastatic, or persistent cervical carcinoma. J Clin Oncol. 2019;37:2538.
32. Silva SD, Nonogaki S, Soares FA, Kowalski LP. P16 (INK4a) has clinicopathological and prognostic impact on oropharynx and larynx squamous cell carcinoma. Brazilian J Med Biol Res. 2012;45(12):1327–33.
33. Fuxe J. p16INK4a and p15INK4b in Senescence, Immortalization and Cancer Gene Transfer by Adenovirus Vectors. 2001.
34. Wai KC, Strohl MP, van Zante A, Ha PK. Molecular Diagnostics in Human Papillomavirus-Related Head and Neck Squamous Cell Carcinoma. Cells. 2020;9(2):1–14.
35. Nicolás I, Saco A, Barnadas E, Marimon L, Rakislova N, Fusté P, et al. Prognostic implications of genotyping and p16 immunostaining in HPV-positive tumors of the uterine cervix. Mod Pathol [Internet]. 2020;33(1):128–37. Available from: <http://dx.doi.org/10.1038/s41379-019-0360-3>
36. Stoler MH, Jr TCW, Ferenczy A, Ranger-moore J, Fang Q, Kapadia M. Routine Use of Adjunctive p16 Immunohistochemistry Improves Diagnostic Agreement of Cervical Biopsy. 2018;42(8):1001–9.
37. Gupta SM, Mania-Pramanik J. Molecular mechanisms in progression of HPV-associated cervical carcinogenesis. J Biomed Sci. 2019;26(1):1–19.
38. Sastroasmoro sudigdo, Ismael S. Dasar-Dasar Metodologi Penelitian Klinis. sagung seto. 2011.

39. V Bhat R, Pari P. A study on expression of p16INK4a by immunohistochemistry in cervical dysplasia and Invasive carcinoma of cervix. *IP Arch Cytol Histopathol Res.* 2020;4(4):310–4.
40. Fu H, Chuang I, Yang Y, Chuang P, Lin H, Ou Y, et al. Low P16 INK4A Expression Associated with High Expression of Cancer Stem Cell Markers Predicts Poor Prognosis in Cervical Cancer after Radiotherapy. 2018;1–15.
41. Abclonal. Immunohistochemistry Protocol (Paraffin). 2014;5670. Available from: https://abclonal.com/Uploads/protocol/IHC-P_protocol.pdf

